No reporter is more plugged into the concerns and opinions of biotechnology investors than STAT's Adam Feuerstein. And, as a result, this Polk Award-winning reporter is also among the most influential writers in the industry and on Wall Street.
At STAT Breakthrough Summit East, Adam will be convening a panel of the top figures from the "buy side" – the usually silent investors who make big calls about what health care stocks to buy and sell. Among them: Patrick Nosker, the director of research at Affinity Asset Advisors, one of the top-performing biotech funds in 2023. If you are an investor or work for a company that has investors, you don't want to miss this.
My team and I have been working hard (I'd say tirelessly but we're tired) to put together an amazing agenda for this event. Here are a few other things that we expect will be on stage on March 21.
In cases from Sarepta's gene therapy (it looks likely to be approved) to Brainstorm's ALS drug (it wasn't approved), patient advocates have seemed to play an increasingly important role in the decisions of the Food and Drug Administration. We'll discuss this with top patient advocates.
GLP-1 obesity drugs have taken the world by storm. But will insurance companies or government payers start to push back? We'll take a close look.
We'll also have a fireside chat with gene editing pioneer Feng Zhang, who lately has been spinning out companies at a stunning pace. I'll interview pioneering patient advocate Kathy Giusti, who changed the treatment of multiple myeloma. And Damian Garde, one of the best storytellers in biotech, will sit down with Mikael Dolsten from Pfizer and Kimberly Smith for a discussion about the state of pharma R&D.
I know I say it every time, but really: I hope to see you there. It will be a blast. You can apply to attend in person at this link.
No comments